"Pragmatica-Lung Study: Streamlining Cancer Clinical Trials for Accessibility and Efficiency"
The National Cancer Institute has launched a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The trial, called the Pragmatica-Lung Study, aims to increase accessibility to clinical trials by using a pragmatic approach that removes many of the barriers that prevent people from joining clinical trials. The trial will evaluate whether a combination of two FDA-approved medications, ramucirumab and pembrolizumab, improves overall survival over standard treatment in people with advanced NSCLC whose disease has progressed after previous treatment with immunotherapy and chemotherapy.